KRAS and pancreatic ductal adenocarcinoma: Despite previous reports that the GLS1 inhibitor CB-839 failed to suppress KRas-driven pancreatic ductal adenocarcinoma growth51 and showed no advantage over standard immunotherapy in stage IV non-small cell lung cancer52, a phase 1b/2 trial found that CB-839 combined with azacytidine is a safe and effective treatment for myelodysplastic syndrome53.